JAK2 and AL amyloidosis: SAR317461, a small molecule inhibitor of JAK2 identified by structure-based drug design [20], was used as it has been shown to potently down-regulate expression of phosphorylated JAK2 and STAT1 without affecting expression of total JAK2 and STAT1 in multiple myeloma cell lines [21].